Sermorelin gets filed next to testosterone and growth hormone in conversation, and it is neither. The classification questions have clean answers, they do not all point the same way, and two of them matter a great deal more than the rest depending on who is asking.
It is not a steroid
Anabolic steroids are built on a four-ring carbon skeleton derived from cholesterol. Sermorelin is a chain of twenty-nine amino acids — a peptide, specifically an analog of growth hormone-releasing hormone. Different molecule, different family, different receptor. Nothing about testosterone's legal status, side-effect profile or monitoring requirements transfers to it.
It is also not growth hormone. Sermorelin signals the pituitary to release more of your own, which is why the downstream markers move rather than the hormone being supplied directly — the chain that sets off is the mechanism the whole category rests on.
It does not appear in the federal drug schedules
On September 14, 2026, sermorelin does not appear anywhere in title 21, part 1308 of the Code of Federal Regulations — the federal schedules of controlled substances [1]. Neither does GHRH, tesamorelin or ipamorelin. Testosterone, nandrolone, oxandrolone and fentanyl all do, which is how we know the search found what was there rather than finding nothing.
That control matters more than it sounds. The first attempt at this check parsed the DEA's own alphabetical list as a PDF, returned 5,623 characters from a 420-kilobyte file, and reported sermorelin absent — along with fentanyl. An absence is only worth publishing when something you expect to find has been found.
Not scheduled is not the same as unregulated
This is where the question usually goes wrong. Growth hormone is also absent from those schedules, and distributing it for unapproved uses is still a federal offense under a separate statute. So “not a controlled substance” establishes one specific thing — that a drug is not in the CSA schedules — and establishes nothing about whether selling, importing or possessing it is lawful in a given circumstance.
Whether any statute written for growth hormone reaches a GHRH analog instead is a question of legal interpretation, and it is not one this desk answers. What is documented is the FDA's own posture toward compounded peptides sold outside the prescription channel, which the prescribed-versus-research-chemical comparison goes through, including the December 2024 letter. If your question is about legality in your situation, the answer comes from a lawyer, not from a product page.
In sport, the answer is unambiguous
The World Anti-Doping Agency prohibits growth hormone-releasing factors under section S2.2.4, naming GHRH and its analogs and listing sermorelin directly alongside CJC-1293, CJC-1295 and tesamorelin. It is prohibited at all times — in and out of competition [2].
So yes, it is a performance-enhancing drug by the definition that governs tested athletes, and that answer holds regardless of what the federal schedules say. It is also the reason the scientific literature connecting sermorelin to sport is mostly detection methodology, as the muscle-growth evidence sets out. Being prohibited and being screened for are still separate questions, and what a standard workplace panel actually tests for answers the second one.
It is a prescription drug, and a compounded one
Every seller reviewed here requires a prescription, and every sermorelin on the US market is compounded, because no approved sermorelin product is on the market for a pharmacy to dispense instead. A compounded preparation is made to order and is not reviewed by the FDA before it reaches you.
The short version: a peptide, not a steroid and not growth hormone; absent from the federal schedules but not therefore unregulated; banned in tested sport at all times; and available only on prescription, as a compounded product.